GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » Additional Paid-In Capital

NKGen Biotech (NKGen Biotech) Additional Paid-In Capital : $122.84 Mil(As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech Additional Paid-In Capital?


NKGen Biotech's quarterly additional paid-in capital increased from Sep. 2023 ($120.80 Mil) to Dec. 2023 ($121.73 Mil) and increased from Dec. 2023 ($121.73 Mil) to Mar. 2024 ($122.84 Mil).

NKGen Biotech's annual additional paid-in capital increased from Dec. 2021 ($14.36 Mil) to Dec. 2022 ($80.74 Mil) and increased from Dec. 2022 ($80.74 Mil) to Dec. 2023 ($121.73 Mil).


NKGen Biotech Additional Paid-In Capital Historical Data

The historical data trend for NKGen Biotech's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech Additional Paid-In Capital Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
Additional Paid-In Capital
14.36 80.74 121.73

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial 80.74 - 120.80 121.73 122.84

NKGen Biotech Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

NKGen Biotech Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


NKGen Biotech (NKGen Biotech) Business Description

Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.